| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00430-017-0531-0 |
| P698 | PubMed publication ID | 29256094 |
| P2093 | author name string | Louis Bont | |
| Fazel Shokri | |||
| Mahmood Mahmoodi | |||
| Talat Mokhtari-Azad | |||
| Ali Ramezani | |||
| Bagher Minaei | |||
| Shahram Shahabi | |||
| Vahid Salimi | |||
| Alireza Tahamtan | |||
| Abbas Jamali | |||
| Mohammad Javad Gharagozlou | |||
| Habib Mirzaei | |||
| Maryam Golaram | |||
| P2860 | cites work | Opioids and Viral Infections: A Double-Edged Sword | Q26742182 |
| Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? | Q28259148 | ||
| mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis | Q28591542 | ||
| The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood | Q33732535 | ||
| In vivo characterization of the opioid antagonist nalmefene in mice | Q33767106 | ||
| Immune responses and disease enhancement during respiratory syncytial virus infection | Q33937152 | ||
| Detection and function of opioid receptors on cells from the immune system | Q33998561 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| New insights for development of a safe and protective RSV vaccine | Q34249859 | ||
| Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials | Q35761061 | ||
| Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern | Q35859950 | ||
| Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. | Q36401415 | ||
| TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity | Q37188620 | ||
| Respiratory syncytial virus--a comprehensive review | Q38098094 | ||
| Effects of cannabinoids and their receptors on viral infections. | Q38522557 | ||
| Prevalence of human respiratory syncytial virus circulating in Iran | Q38542814 | ||
| Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics | Q38594067 | ||
| Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study | Q38687853 | ||
| The role of microRNAs in respiratory viral infection: friend or foe? | Q38884668 | ||
| Protective and Harmful Immunity to RSV Infection. | Q39146784 | ||
| Vaccine development for respiratory syncytial virus | Q39318444 | ||
| Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice | Q39808511 | ||
| Evaluation of the expression level of 12/15 lipoxygenase and the related inflammatory factors (CCL5, CCL3) in respiratory syncytial virus infection in mice model. | Q40173386 | ||
| Mixture of Alum--Naloxone and Alum--Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB /c mice | Q40831361 | ||
| Beta-endorphin in the immune system: a role at last? | Q41546319 | ||
| Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. | Q41921462 | ||
| The opioid antagonist naloxone inhibits Leishmania major infection in BALB/c mice | Q44331194 | ||
| Opioid receptors control viral replication in the airways | Q44337050 | ||
| A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine | Q44341358 | ||
| A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. | Q44348323 | ||
| A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei | Q47875209 | ||
| Neurokinin-1 receptor interacts with PrP(106-126)-induced dendritic cell migration and maturation | Q81119747 | ||
| P577 | publication date | 2017-12-18 | |
| P1433 | published in | Medical Microbiology and Immunology | Q15760239 |
| P1476 | title | Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts |
Search more.